​

Q: What is multiple myeloma? 

A: Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. Plasma cells are a type of white blood cell that produce antibodies to help fight infections. In myeloma, these plasma cells become cancerous and start producing abnormal antibodies (M proteins), which do not help the immune system and can damage the kidneys. 

Types of Myeloma: 

• Smoldering Myeloma (SMM) – Slow-growing, does not require immediate treatment. 

• Multiple Myeloma (MM) – Most common form, affects multiple bones in the body. 

• Solitary Plasmacytoma – A single tumor in the bone or soft tissue. 

 

Q: Who is at risk of developing multiple myeloma? 

A: The exact cause is unknown, but some risk factors include: 

• Age: Most common in people over 65 years old. 

• Gender: More common in men than women. 

• Race: Higher risk in African Americans. 

• Family history: Having a close relative with myeloma may increase risk. 

• Exposure to toxic chemicals: Long-term exposure to benzene, pesticides, or radiation. 

• Monoclonal Gammopathy of Undetermined Significance (MGUS): A precursor condition that can develop into myeloma. 

• Obesity: Increased risk linked to excess body weight. 

 

Q: What are the common symptoms of multiple myeloma? 

A: Many patients do not experience symptoms in the early stages. When symptoms do appear, they may include: 

• Bone pain (especially in the spine, ribs, and hips). 

• Fatigue and weakness (due to anemia). 

• Frequent infections (due to a weakened immune system). 

• Unexplained weight loss. 

• Excessive thirst and frequent urination (signs of kidney damage). 

• Numbness or tingling in the legs (due to spinal cord compression). 

• Easy bruising or bleeding (due to low platelet count). 

Doctors use the CRAB criteria to identify active myeloma: 

• C – Calcium elevation (Hypercalcemia → bone breakdown releases calcium into the blood). 

• R – Renal (kidney) failure (High M protein can damage kidneys). 

• A – Anemia (Low red blood cell count causes fatigue). 

• B – Bone abnormalities (Bone lesions, fractures, or osteoporosis). 

If any of these symptoms are present, consult a doctor for further testing. 

 

Q: What tests are used to diagnose multiple myeloma? 

A: A diagnosis involves blood tests, urine tests, imaging, and bone marrow biopsy. 

1. Blood Tests: Serum Protein Electrophoresis (SPEP) – Measures M protein levels. 

2. Serum Free Light Chain Test – Detects abnormal light chains. 

3. Complete Blood Count (CBC) – Checks for anemia. 

4. Calcium and Creatinine Levels – Detects hypercalcemia and kidney damage. 

5. Urine Tests: Bence Jones Protein Test – Detects light chains in urine. 

6. Bone Marrow Biopsy: Checks for cancerous plasma cells in the bone marrow. 

7. Imaging Tests: X-ray, MRI, CT scan, PET scan – Detects bone lesions and fractures. 

 

Q: How is multiple myeloma treated? 

A: Treatment depends on disease stage, symptoms, and overall health. 

1. Smoldering Myeloma (SMM) 

• Watch-and-Wait Approach: No immediate treatment, but regular monitoring. 

2. Active Multiple Myeloma 

• Combination Drug Therapy (Standard First-Line Treatment) 

• Proteasome Inhibitors: 

• Bortezomib (Velcade), Carfilzomib (Kyprolis), Ixazomib (Ninlaro) – Prevent myeloma cell growth. 

• Immunomodulatory Drugs (IMiDs): 

• Lenalidomide (Revlimid), Pomalidomide (Pomalyst), Thalidomide – Boost the immune response. 

• Steroids: 

• Dexamethasone, Prednisone – Reduce inflammation and slow myeloma growth. 

• High-Dose Chemotherapy + Stem Cell Transplantation 

• Autologous Stem Cell Transplant (ASCT) – Uses a patient’s own stem cells. 

• Allogeneic Stem Cell Transplant (Rarely Used) – Uses a donor’s stem cells. 

• Targeted Therapy 

• Daratumumab (Darzalex), Elotuzumab (Empliciti) – Monoclonal antibodies for refractory myeloma. 

• Venetoclax – Used in t(11;14) genetic mutation myeloma. 

• CAR-T Cell Therapy (New Immunotherapy) 

• Idecabtagene vicleucel (Abecma) and Ciltacabtagene autoleucel (Carvykti) – Engineered immune cells attack myeloma cells. 

• Bispecific Antibodies (Newest Therapies, 2024) 

• Teclistamab – A new T-cell engager for relapsed multiple myeloma. 

• Radiation Therapy 

• Used for solitary plasmacytoma or bone pain relief. 

• Clinical Trials 

• Many new immunotherapies and combination treatments are in development. 

  

Q: What is the survival rate for multiple myeloma? 

A: Survival depends on disease stage, genetics, and response to treatment. 

• Smoldering Myeloma (SMM) – May remain stable for years before progressing. 

• Multiple Myeloma – 

• Standard-risk myeloma: ~6-10 year survival with modern treatments. 

• High-risk myeloma (e.g., 17p deletion, t(4;14) mutation): Shorter survival, but new therapies are improving outcomes. 

• CAR-T Cell Therapy and Bispecific Antibodies are increasing survival rates, even for relapsed patients. 

 

Q: What new treatments are available for multiple myeloma? 

A: 

• CAR-T Cell Therapy (Abecma, Carvykti) – Highly effective for relapsed/refractory myeloma. 

• Teclistamab (Bispecific Antibody) – A promising immunotherapy. 

• New Proteasome Inhibitors (e.g., Oprozomib) – Under investigation. 

• Next-Generation IMiDs (e.g., Iberdomide) – Showing promise in clinical trials. 

These new treatments are extending survival and improving quality of life. 

 

Q: Can multiple myeloma be prevented? 

A: There is no guaranteed way to prevent myeloma, but you can lower your risk by: 

• Avoiding exposure to toxic chemicals (e.g., benzene, pesticides). 

• Maintaining a healthy diet and regular exercise. 

• Monitoring MGUS or SMM if diagnosed.